Almirall Issues Cautious Q1 2026 Financial and Business Update

Almirall ( (ES:ALM) ) has issued an update.

Almirall has released a presentation of its Q1 2026 financial results and business update, prepared primarily for internal and investor communication purposes. The document emphasizes that the information is summarized, may differ from the authoritative English version, and should not be used as a comprehensive or definitive source on the company’s performance or securities.

The company underscores that past share price performance cannot be used as an indicator of future results and that the document contains forward‑looking statements based on internal estimates and assumptions. It stresses that these statements have not been independently verified, may differ materially from actual outcomes due to risks and uncertainties, and do not constitute an offer or solicitation to buy, sell, or subscribe to its securities in any jurisdiction.

The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.

More about Almirall

Almirall is a pharmaceutical company focused on developing and marketing prescription medicines, with a particular emphasis on dermatology and other specialty therapeutic areas. The company operates globally and targets both primary care and specialist markets, positioning itself as an innovation‑driven player in the healthcare industry.

Average Trading Volume: 149,849

Technical Sentiment Signal: Buy

Current Market Cap: €2.57B

See more insights into ALM stock on TipRanks’ Stock Analysis page.